Literature DB >> 8823531

Molecular genetics of hyperparathyroid disease.

Y Tominaga1, H Takagi.   

Abstract

Information on genetic abnormalities in primary hyperparathyroidism has accumulated gradually. Genetic alterations responsible for tumorigenesis have been identified in multiple endocrine neoplasia types 1 and 2. Point mutations in a calcium-sensing receptor gene were recently found to be responsible for familial hypocalciuric hypercalcaemia and neonatal severe hyperparathyroidism. Evidence has been provided that abnormalities of cell cycle regulation participate at tumorigenesis in parathyroid adenoma and carcinoma. Clonal analysis has shown that in renal hyperparathyroidism the parathyroid glands initially grow diffusely and polyclonally, after which foci of nodular hyperplasia are transformed to monoclonal neoplasia. Somatic changes of specific genes have been suspected of being responsible for parathyroid tumorigenesis in renal hyperparathyroidism. However, the genetic loci responsible for the frequent monoclonality largely remain to be identified, and heterogeneous genetic abnormalities may contribute to the progression of secondary parathyroid hyperplasia.

Entities:  

Mesh:

Year:  1996        PMID: 8823531     DOI: 10.1097/00041552-199607000-00008

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  12 in total

1.  Molecular characterization of parathyroid tumors from two patients with hereditary colorectal cancer syndromes.

Authors:  Adam Andreasson; Luqman Sulaiman; Sónia do Vale; João Martin Martins; Florbela Ferreira; Gabriel Miltenberger-Miltenyi; Lucas Batista; Felix Haglund; Erik Björck; Inga-Lena Nilsson; Anders Höög; Catharina Larsson; C Christofer Juhlin
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 2.  Phosphate control in end-stage renal disease: barriers and opportunities.

Authors:  Ahmed A Waheed; Fernando Pedraza; Oliver Lenz; Tamara Isakova
Journal:  Nephrol Dial Transplant       Date:  2013-07-30       Impact factor: 5.992

3.  The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.

Authors:  M Wada; Y Furuya; J Sakiyama; N Kobayashi; S Miyata; H Ishii; N Nagano
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 4.  Secondary hyperparathyroidism: pathophysiology, histopathology, and medical and surgical management.

Authors:  Y Tominaga; H Johansson; H Johansson; H Takagi
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

Review 5.  Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.

Authors:  Mohamed Abdelgadir Adam; Brian R Untch; John A Olson
Journal:  Oncologist       Date:  2010-01-05

6.  Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease.

Authors:  Yoshihiro Tominaga; Toyonori Tsuzuki; Susumu Matsuoka; Nobuaki Uno; Tetsuhiko Sato; Syuichi Shimabukuro; Norihiko Goto; Takaharu Nagasaka; Kazuharu Uchida
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

7.  EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.

Authors:  Margit Hemetsberger; Rainer Oberbauer; Helmut Erb; Wolfgang Pronai
Journal:  Wien Med Wochenschr       Date:  2015-08-25

8.  Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.

Authors:  H Funahashi; Y Tanaka; T Imai; M Wada; K Tsukamura; Y Hayakawa; N Matsuura; T Kikumori; M Oiwa; Y Tominaga; H Takagi
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

9.  A reference finding rarely seen in primary hyperparathyroidism: brown tumor.

Authors:  F Mantar; S Gunduz; U R Gunduz
Journal:  Case Rep Med       Date:  2012-11-21

10.  Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth.

Authors:  Masatomo Taniguchi; Masanori Tokumoto; Kazuhiko Tsuruya; Hideki Hirakata; Mitsuo Iida
Journal:  Nephrol Dial Transplant       Date:  2008-05-30       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.